Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cipla
UBS
McKesson
Merck
Moodys

Generated: September 18, 2019

DrugPatentWatch Database Preview

NEUPRO Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which patents cover Neupro, and when can generic versions of Neupro launch?

Neupro is a drug marketed by Ucb Inc and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-seven patent family members in thirty-seven countries.

The generic ingredient in NEUPRO is rotigotine. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rotigotine profile page.

Drug patent expirations by year for NEUPRO
Generic Entry Opportunity Date for NEUPRO
Generic Entry Date for NEUPRO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FILM, EXTENDED RELEASE;TRANSDERMAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for NEUPRO
(-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol
(-)-N-0437
(2S)-2-[propyl-[2-(2-thienyl)ethyl]amino]tetralin-5-ol
(6S)-6-(propyl-(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
(6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol
(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol
(S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol
(S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
(S)-6-[Propyl-(2-thiophen-2-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol
1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-
1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (6S)-
2696AH
572R932
87T4T8BO2E
99755-59-6
A846076
AB0088886
AC-3547
AC1L1QQG
AJ-08188
AKOS016340728
AN-12885
API0026245
BC677693
BDBM50123626
C19H25NOS
CAS-99755-59-6
CHEBI:135351
CHEMBL1303
CS-0376
CTK8E7903
D05768
DB05271
DSSTox_CID_26772
DSSTox_GSID_46772
DSSTox_RID_81893
DTXSID5046772
EX-A1164
FT-0771906
GTPL941
HSDB 8254
HY-75502
J-502471
KFQYTPMOWPVWEJ-INIZCTEOSA-N
KS-00002WXX
Leganto
LS-178435
MolPort-005-941-578
N 0437, (-)-isomer
N 0923
N-0923
NCGC00168748-01
NCGC00168748-02
Neupro (TN)
PubChem16423
RL06136
Rotigotine
Rotigotine (JAN/USAN/INN)
Rotigotine [USAN:INN:BAN]
Rotigotine [USAN:INN]
Rotigotine CDS
Rotigotine CDS Patch
RT-015446
s4274
SB19528
SC-22242
SCHEMBL1088585
SPM 962
SPM-936
SPM-937
SPM-962
SS-4572
SW220014-1
Tox21_112627
Tox21_112627_1
UNII-5QTR54Z0E1 component KFQYTPMOWPVWEJ-INIZCTEOSA-N
UNII-87T4T8BO2E
W-5179
ZINC4028

US Patents and Regulatory Information for NEUPRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for NEUPRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007   Try a Free Trial   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012   Try a Free Trial   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012   Try a Free Trial   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007   Try a Free Trial   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012   Try a Free Trial   Try a Free Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for NEUPRO
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Transdermal Film 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr ➤ Subscribe   Try a Free Trial

Supplementary Protection Certificates for NEUPRO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1033978 C01033978/01 Switzerland   Try a Free Trial TEILUEBERTRAGUNG
1033978 C300236 Netherlands   Try a Free Trial PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001-013 20060215
1033978 24/2006 Austria   Try a Free Trial PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 - EU/1/05/331/013 20060215
1033978 CA 2006 00020 Denmark   Try a Free Trial PRODUCT NAME: ROTIGOTINE
1033978 SPC026/2006 Ireland   Try a Free Trial SPC026/2006:, EXPIRES: 20210214
1033978 SZ 24/2006 Austria   Try a Free Trial PRODUCT NAME: ROTIGOTINE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Baxter
Medtronic
McKesson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.